Back to news

Cytokinetics Announces Prescribing Information for MYQORZO® (aficamten) Expanded to Include Data from Phase 3 MAPLE-HCM

Globe Newswire•16/11/2026•04:00 ET
0

Key Highlights

  • ➤FDA approved U.S. label expansion for MYQORZO (CYTK) with MAPLE-HCM data
  • ➤MAPLE-HCM showed MYQORZO significantly improved exercise capacity versus metoprolol
  • ➤MAPLE-HCM showed MYQORZO significantly improved symptoms versus metoprolol
  • ➤MAPLE-HCM showed MYQORZO significantly improved cardiac biomarkers versus metoprolol
  • ➤MYQORZO carries a Boxed WARNING for heart failure risk from systolic dysfunction

Expert Statements

Robert I. Blum, President and Chief Executive Officer of Cytokinetics

“People living with HCM deserve treatment decisions grounded in rigorous evidence. For decades, beta-blockers have been a cornerstone of treatment for oHCM in the absence of rigorously conducted clinical trials demonstrating their utility in this condition.”

Robert I. Blum, President and Chief Executive Officer of Cytokinetics

“In MAPLE-HCM, MYQORZO demonstrated significantly greater improvements in exercise capacity, symptom burden and cardiac biomarkers compared to metoprolol. MYQORZO is now the only cardiac myosin inhibitor with evidence comparing its effectiveness to a beta-blocker for the treatment of oHCM in its U.S. label, providing cardiologists and patients important information to inform treatment decisions.”

MYQORZO is the Only Cardiac Myosin Inhibitor with Data in Its U.S. Label Comparing Its Effectiveness to the Beta Blocker Metoprolol

SOUTH SAN FRANCISCO, Calif., Nov. 16, 2026 (GLOBE NEWSWIRE) -- Cytokinetics, Incorporated (Nasdaq: CYTK) today announced that the U.S. Food and Drug Administration (FDA) has approved a supplemental New Drug Application (sNDA) updating the U.S. Prescribing Information for MYQORZO(®) (aficamten) to include data from MAPLE-HCM, the Phase 3 trial comparing MYQORZO and the standard-of-care beta-blocker metoprolol, each as monotherapy, in adults with symptomatic obstructive hypertrophic cardiomyopathy (oHCM). MYQORZO is indicated for the treatment of adults with symptomatic oHCM to improve functional capacity and symptoms.

Get started

Create a free account to read the full story.

Sign Up

Already have an account? Log in